By the Top Tier Newswire AI Desk · July 17, 2026 at 1:18 PM ET · reviewed against 19 wire stories
GLOBUS MED INC A (GMED) is down -12.76% in the latest session. Our newswire has captured 19 stories on GMED across 10 sources in the last 36 hours, with AI sentiment reading mixed (avg 46/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Globus Medical Inc. A (GMED) fell 4.92% to $76.93 on Monday, marking a sharp decline in early trading. The move came ahead of the company's scheduled second-quarter earnings release and conference call set for July 30, 2026. The stock opened at $81.05 but quickly fell to a session low of $76.75 before settling near $76.96. The drop occurred amid mixed analyst coverage and recent insider selling activity.
What Happened
Globus Medical announced that its second-quarter earnings will be released ahead of market open on July 30, 2026, with a conference call scheduled for 4:30 p.m. ET. The company will provide results for the period ending June 30, 2026. Investors can access the webcast and audio archive online. The announcement coincided with a broader market rally driven by AI chip developments, but GMED faced pressure from recent analyst actions and internal selling. Truist Securities and RBC Capital both cut price targets, while Stifel lowered its target to $80 and maintained a Hold rating. BMO Capital initiated coverage with an Outperform rating and a $94 price target. Meanwhile, Davidar David D, a director, sold shares on June 5, 2026, and total insider sales over the past 90 days reached $2.0 million.
What The Data Shows
The stock’s intraday move reflected early weakness, with volume reaching 0.7 million shares, or 0.5 times the 3-month average. GMED has a market cap of $10.3 billion and a P/E ratio of 18.9. Revenue has grown 23.5% in the trailing twelve months, with a net margin of 18.9%. The stock has traded between $51.79 and $101.40 over the past 52 weeks. The recent pullback has brought the stock closer to the lower end of its 52-week range, raising questions about earnings expectations and analyst sentiment.
What To Watch
Investors will turn to the July 30 earnings report and conference call for clarity on the company’s performance. The coverage landscape remains mixed, with some analysts lowering price targets and others maintaining bullish stances. The market will also watch for further insider activity and how the stock reacts to earnings.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
GMED · Jul 17 session (5-min) · -4.83% vs prior close · updated 8:59 PM ETAI sentiment, last 36h · averaged over 19 stories · 46/100 neutral
The headlines behind the move
Story flow · 10 stories on the wire, last 36h · hover or tap a dot for the headline
1h agoGuruFocusBEARISH 42Analyst
GMED Maintained by Canaccord Genuity -- Price Target Lowered to $105
2h agoBarchartBEARISH 31General
Why Globus Medical (GMED) shares are plunging today
Why Globus Medical (GMED) shares are plunging today
4h agoThe FlyBEARISH 34Analyst
Globus Medical price target lowered to $90 from $100 at Truist
4h agoInvesting.com MarketsBEARISH 34General
Why is Globus Medical stock plunging today?
Why is Globus Medical stock plunging today?
7h agoGuruFocusNEUTRAL 52Analyst
GMED Maintained by Needham -- Price Target Lowered to $100
Globus Medical (GMED) Analyst Rating Update On October 1, 2023, Needham maintained a 'Buy' rating for Globus Medical Inc. (GMED), adjusting the price target
7h agoThe FlyBULLISH 61Analyst
Globus Medical price target raised to $100 from $99 at Wells Fargo
10h agoThe FlyBEARISH 34Analyst
Globus Medical downgraded to Market Perform from Outperform at BMO Capital
BMO Capital downgrades Globus Medical stock rating to Market Perform
BMO Capital downgrades Globus Medical stock rating to Market Perform
14h agoThe Motley FoolNEUTRAL 48Earnings
Globus Medical (GMED) Q3 2026 Earnings Call Transcript
Record free cash flow offset a revenue dip and a lower full-year outlook.
Frequently asked questions
Why is GMED stock down today?
GLOBUS MED INC A (GMED) is down -12.76% in the latest session. Our newswire has captured 19 stories on GMED across 10 sources in the last 36 hours, with AI sentiment reading mixed (avg 46/100). The most recent driver: "GMED Maintained by Canaccord Genuity -- Price Target Lowered to $105" (GuruFocus).
Is GMED a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of GMED coverage reads 46/100 over 19 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →